866-997-4948(US-Canada Toll Free)

Human Immunodeficiency Virus (HIV) Infections (AIDS) Global Clinical Trials Review, H2, 2017

Published By :

GlobalData

Published Date : Sep 2017

Category :

Pharmaceutical

No. of Pages : 2941 Pages

Human Immunodeficiency Virus (HIV) Infections (AIDS) Global Clinical Trials Review, H2, 2017

Summary

GlobalData's clinical trial report, Human Immunodeficiency Virus (HIV) Infections (AIDS) Global Clinical Trials Review, H2, 2017" provides an overview of Human Immunodeficiency Virus (HIV) Infections (AIDS) clinical trials scenario. This report provides top line data relating to the clinical trials on Human Immunodeficiency Virus (HIV) Infections (AIDS). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
Top Five Countries Contributing to Clinical Trials in Europe 13
Top Countries Contributing to Clinical Trials in North America 14
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
Top Five Countries Contributing to Clinical Trials in Central and South America 16
Clinical Trials by G7 Countries: Proportion of Human Immunodeficiency Virus (HIV) Infections (AIDS) to Infectious Disease Clinical Trials 17
Clinical Trials by Phase in G7 Countries 19
Clinical Trials in G7 Countries by Trial Status 20
Clinical Trials by E7 Countries: Proportion of Human Immunodeficiency Virus (HIV) Infections (AIDS) to Infectious Disease Clinical Trials 21
Clinical Trials by Phase in E7 Countries 22
Clinical Trials in E7 Countries by Trial Status 23
Clinical Trials by Phase 24
In Progress Trials by Phase 25
Clinical Trials by Trial Status 26
Clinical Trials by End Point Status 27
Subjects Recruited Over a Period of Time 28
Clinical Trials by Sponsor Type 29
Prominent Sponsors 30
Top Companies Participating in Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Clinical Trials 31
Prominent Drugs 32
Latest Clinical Trials News on Human Immunodeficiency Virus (HIV) Infections (AIDS) 33
Sep 18, 2017: ABIVAX: First Patient Dosed in Three-Month Cohort of Phase 2a Study of Oral ABX464 in HIV-Suppressed Patients 33
Sep 13, 2017: Mymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines 33
Sep 11, 2017: Abivax Presents Full ABX464 Positive Phase 2a Clinical HIV Data at the HIV Cure and Reservoir Symposium 33
Sep 06, 2017: Argos Announces First Dosing of HIV Patient with AGS-004 Derived from the Latent Viral Reservoir 34
Sep 06, 2017: CytoDyn Provides Further Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV 34
Sep 05, 2017: AELIX Therapeutics enrolls first patient in companys initial therapeutic HIV vaccine clinical trial 35
Sep 05, 2017: MacroGenics Advances Development of its DART candidate MGD014 35
Aug 18, 2017: GSK releases positive interim results from the DAWNING study on efficacy of dolutegravir (Tivicay) 35
Jul 27, 2017: BIT225 Phase 2 HIV-1 Clinical Trial Fully Recruited 36
Jul 26, 2017: Argos Reports Immunogenicity Results of AGS-004 in HIV Program 36
Jul 25, 2017: Janssen Announces Phase 3 Pivotal Study Results For Darunavir-Based Complete Treatment Regimen 37
Jul 25, 2017: Merck's Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection 37
Jul 25, 2017: ViiV Healthcare announces superior efficacy of dolutegravir versus lopinavir/ritonavir in second-line HIV treatment in resource-limited settings 38
Jul 25, 2017: Switching to a dolutegravir regimen from a boosted protease inhibitor regimen maintained viral suppression and improved lipid fractions in patients with HIV and high cardiovascular risk 39
Jul 25, 2017: Long-Acting Injectable Cabotegravir for PrEP Well Tolerated in HPTN 077: Results Support Dosing Regimens in HPTN 083 and HPTN 084 40
Jul 24, 2017: Merck Announces Week 96 Results from ONCEMRK, A Study Evaluating Once-Daily ISENTRESS HD (raltegravir), in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appropriate Patients 40
Jul 24, 2017: Phase II study results showed comparable viral suppression rates at 96 weeks for a two-drug regimen of long-acting cabotegravir and rilpivirine and a three-drug regimen in patients with HIV 41
Jul 24, 2017: Gilead Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV 41
Jul 24, 2017: Theratechnologies Announces New Findings with Investigational Antiretroviral EGRIFTA (tesamorelin for injection) 42
Jul 24, 2017: Theratechnologies Announces New Findings from Investigational Antiretroviral Ibalizumab 42
Jul 24, 2017: Experimental HIV Vaccine Regimen is Well-Tolerated, Elicits Immune Responses 42
Jul 20, 2017: ViiV Healthcare Presents Abstracts of Dolutegravir at IAS 2017 43
Jul 20, 2017: ViiV Healthcare Presents on Cabotegravir at IAS 2017 44
Jul 13, 2017: ABIVAX to present latest clinical data on ABX464 at the International Aids Society Conference in Paris, France 44
Jul 06, 2017: Merck to Present New Data on ISENTRESS HD at the 9th IAS Conference on HIV Science 45
Jul 06, 2017: Merck Announces Presentation on Doravirine at IAS 2017 45
Jul 06, 2017: Merck to Present Data from on MK-8591 at IAS 2017 46
Clinical Trial Profile Snapshots 47
Appendix 2939
Abbreviations 2939
Definitions 2939
Research Methodology 2940
Secondary Research 2940
About GlobalData 2941
Contact Us 2941
Source 2941

List of Tables
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics, Global, Clinical Trials by Region, 2017* 8
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 15
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 16
Proportion of Human Immunodeficiency Virus (HIV) Infections (AIDS) to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 18
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
Proportion of Human Immunodeficiency Virus (HIV) Infections (AIDS) to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 21
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 22
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 23
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics, Global, Clinical Trials by Phase, 2017* 24
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 25
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 26
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 29
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 30
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32

List of Figures
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 15
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 16
Proportion of Human Immunodeficiency Virus (HIV) Infections (AIDS) to Infectious Disease Clinical Trials, G7 Countries (%), 2017* 17
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
Proportion of Human Immunodeficiency Virus (HIV) Infections (AIDS) to Infectious Disease Clinical Trials, E7 Countries (%), 2017* 21
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 22
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 23
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 24
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 25
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 26
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 27
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 28
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 29
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 30
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 31
Human Immunodeficiency Virus (HIV) Infections (AIDS) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 32
GlobalData Methodology 2940

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *